Lovastatin therapy for cholesterol ester storage disease in two sisters (Q43846827)

27 November 2017

Lovastatin therapy for cholesterol ester storage disease in two sisters (English)

1 reference

cholesterol ester storage disease

27 November 2017

1 reference

Tarantino MD

1

1 reference

27 November 2017

McNamara DJ

2

1 reference

27 November 2017

Granstrom P

3

1 reference

27 November 2017

Ellefson RD

4

1 reference

27 November 2017

Unger EC

5

1 reference

27 November 2017

Udall JN Jr

6

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 1991

1 reference

The Journal of Pediatrics

27 November 2017

1 reference

27 November 2017

118

1 reference

27 November 2017

131-135

1 reference

27 November 2017

1

1 reference

Hepatic cholesterol ester storage disease, a familial disorder. I. Clinical aspects

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Cholesterol ester storage disease: clinical, biochemical, and pathological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Acid esterase activity in cultured skin fibroblasts and amniotic fluid cells using 4-methylumbelliferyl palmitate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

The relation of liver fat to computed tomography numbers: a preliminary experimental study in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Accuracy of computed tomography in diagnosis of fatty liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Computed tomography in the diagnosis of fatty liver: total lipid content and computed tomography number

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Enzyme replacement therapy in fibroblasts from a patient with cholesteryl ester storage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Efficacy and long-term adverse effect pattern of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

CT findings in acid lipase deficiency: wolman disease and cholesteryl ester storage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

HMG CoA reductase inhibitors. Current clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981866-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(05)81866-9

1 reference

27 November 2017

1 reference